Status:
COMPLETED
Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
Lead Sponsor:
Nagoya University
Conditions:
Hypertension
Type 2 Diabetes Mellitus
Eligibility:
All Genders
30-75 years
Phase:
PHASE4
Brief Summary
Various guidelines recommended angiotensin converting enzyme (ACE) inhibitors or angiotensin Ⅱ receptor-1 blockers (ARBs) for hypertensive patients with diabetes on the basis of the cardiac- and reno-...
Eligibility Criteria
Inclusion
- Clinical diagnosis of hypertension
- Clinical diagnosis of type 2 diabetes or impaired glucose tolerance
Exclusion
- History of congestive heart failure, myocardial infarction, or coronary revascularization in the recent 6 months.
- Taking calcium channel blocker for the purpose of angina pectoris
- Reduced ejection fraction (\< 40%)
- Second- or third-degree of atrioventricular block
- Severe hypertension (\> 200/110 mmHg) or secondary hypertension
- History of stroke in the recent 6 months
- Serum creatinine \> 2.5 mg/dl
- Estimated survival duration less than 3 years due to other conditions
- Pregnant woman or possibly pregnant woman
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
1150 Patients enrolled
Trial Details
Trial ID
NCT00129233
Start Date
October 1 2004
End Date
April 1 2013
Last Update
May 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiology, Nagoya University Graduate School of Medicine
Nagoya, Aichi-ken, Japan, 466-8550